{"prompt": "['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', '-', 'Absolute neutrophil count (ANC) > 1.5 X 109/L', '-', 'Platelet count > 100 X 109/L', '-', 'Total bilirubin < 1.5 X institutional upper limit of normal (ULN)', '-', 'Aspartate aminotransferase (AST) (Serum Glutamic Oxaloacetic Transaminase', '(SGOT)) / Alanine aminotransferase (ALT) (Serum Glutamic Pyruvate', 'Transaminase (SGPT)) < 2.5 X institutional upper limit of normal unless liver', 'metastases are present in which case they must be VI 5x ULN', '-', 'Patients must have creatinine clearance estimated using the Cockcroft-Gault', 'equation or based on 24 hour urine test of >51 mL/min:', 'Estimated creatinine clearance =', '(140-age [years]) X weight (kg)', 'serum creatinine (mg/dL) X 72', '10. Eastern Cooperative Oncology Group (ECOG) performance status 0-1 (see Appendix 2).', '11. Patients must have a life expectancy > 16 weeks.', '12. Male patients and their partners, who are sexually active and of childbearing potential,', 'must agree to the use of two highly effective forms of contraception in combination [see', 'Appendix 3 for acceptable methods], throughout the period of taking study treatment and', 'for 3 months after last dose of study drug(s) to prevent pregnancy in a partner.', '13. Patient is willing and able to comply with the protocol for the duration of the study', 'including undergoing treatment and scheduled visits and examinations.', '14. At least one lesion (measurable and/or non-measurable) that can be accurately assessed at', 'baseline by CT, PET, MRI and/or bone scan and is suitable for repeated assessment.', '15. Must have archival tissue available, be willing to undergo metastatic biopsy or have a', 'sufficient plasma ctDNA concentration in order to perform next-generation DNA', 'sequencing.', '16. The study will require that 50% of enrolled subjects have homozygous deletions,', 'deleterious mutations, or both in one or more of the DDR genes listed in Appendix 5. The', 'other 50% of patients must have an intact DDR pathway (i.e., no mutations/deletions in', 'genes listed in Appendix 5)[88].', '3.2', 'Exclusion criteria', 'Patients should not enter the study if any of the following exclusion criteria are fulfilled:', '1.', 'Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff', 'and/or staff at the study site)', '33(93)', 'Printed on 3/25/202']['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', '2. Previous enrollment in this study', '3. Participation in another clinical study with an investigational product during the last 3', 'weeks', '4. Any previous treatment with PARP inhibitor, including olaparib.', '5. Other malignancy unless curatively treated with no evidence of disease for >5 years', 'except: adequately treated non-melanoma skin cancer.', '6. Resting ECG indicating uncontrolled, potentially reversible cardiac conditions, as judged', 'by the investigator (e.g., unstable ischemia, uncontrolled symptomatic arrhythmia,', 'congestive heart failure, QTcF prolongation >500 ms, electrolyte disturbances, etc.), or', 'patients with congenital long QT syndrome', '7. Patients receiving any systemic chemotherapy or radiotherapy (except for palliative', 'reasons) within 3 weeks prior to study treatment', '8. Concomitant use of known strong CYP3A inhibitors (eg. itraconazole, telithromycin,', 'clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir,', 'saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (eg.', 'ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required washout', 'period prior to starting olaparib is 2 weeks.', '9. Concomitant use of known strong (eg. phenobarbital, enzalutamide, phenytoin, rifampicin,', \"rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort ) or moderate\", 'CYP3A inducers (eg. bosentan, efavirenz, modafinil). The required washout period prior', 'to starting olaparib is 3 weeks for enzalutamide, 5 weeks for phenobarbital and 3 weeks', 'for other agents.', '10. Persistent toxicities (>Common Terminology Criteria for Adverse Event (CTCAE) grade', '2) caused by previous cancer therapy, excluding alopecia.', '11. Patients with myelodysplastic syndrome/acute myeloid leukemia or with features', 'suggestive of MDS/AML.', '12. Patients with symptomatic uncontrolled brain metastases. A scan to confirm the absence', 'of brain metastases is not required. The patient can receive a stable dose of corticosteroids', 'before and during the study as long as these were started at least 4 weeks prior to', 'treatment. Patients with spinal cord compression unless considered to have received', 'definitive treatment for this and evidence of clinically stable disease for 28 days.', '13. Major surgery within 2 weeks of starting study treatment and patients must have recovered', 'from any effects of any major surgery.', '14. Patients considered a poor medical risk due to a serious, uncontrolled medical disorder,', 'non-malignant systemic disease or active, uncontrolled infection. Examples include, but', '34(93)', 'Printed on 3/25/202']\n\n###\n\n", "completion": "END"}